Related Experiment Videos
Antiphospholipid antibodies: predictive value of laboratory tests
1Division of Haematology, Ospedali Riunlti, Bergamo, Italy. ematologia@cyberg.it
Thrombosis and Haemostasis
|July 1, 1997
Summary
Antiphospholipid antibodies (aPL) are linked to thrombosis in Antiphospholipid Syndrome (APS). Further research is needed to standardize tests for identifying high-risk aPL antibodies for better clinical management.
Area of Science:
- Immunology
- Hematology
- Autoimmunity
Background:
- Antiphospholipid (aPL) antibodies are a diverse group of autoantibodies.
- Initially thought to target anionic phospholipids, they are now known to target plasma proteins like beta 2-glycoprotein I and prothrombin.
- These antibodies are associated with Antiphospholipid Syndrome (APS), characterized by thrombosis, recurrent miscarriages, and thrombocytopenia.
Purpose of the Study:
- To review the role of aPL antibodies and Lupus Anticoagulants (LA) in thrombosis.
- To highlight the heterogeneity of aPL antibodies and their varying risk association with thrombosis.
- To emphasize the need for improved diagnostic assays for predicting thrombosis risk in APS.
Main Methods:
- Review of retrospective, cross-sectional, and prospective studies.
- Analysis of existing literature on aCL antibodies and Lupus Anticoagulants.
- Discussion of laboratory test performance in relation to thrombosis risk.
Main Results:
- Studies confirm aPL antibodies and LA as risk factors for venous and arterial thrombosis in APS.
- Evidence suggests that aCL-type A antibodies, but not all LA antibodies, are associated with thrombosis risk.
- Current information on the predictive value of laboratory tests for thrombosis remains limited.
Conclusions:
- aPL antibodies are heterogeneous, with specific types posing a greater thrombosis risk.
- Standardization of assays to identify thrombosis-predictive aPL antibodies is crucial.
- Improved diagnostic tools will aid clinicians in developing targeted therapeutic strategies for APS patients.